ASCO 2020: Researchers underscore efficacy of pembrolizumab plus axitinib in treating advanced renal cell carcinoma - ecancer

$ 15.50

4.7 (236) In stock

Researchers at Fox Chase Cancer Center, along with an international team of investigators, have found that the use of pembrolizumab in combination with axiti

PDF) Extensive intratumor regional epigenetic heterogeneity in clear cell renal cell carcinoma targets kidney enhancers and is associated with poor outcome

Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial - ScienceDirect

ASCO 2021: Pembrolizumab Versus Placebo as Post-Nephrectomy Adjuvant Therapy for Patients with Renal Cell Carcinoma: Randomized, Double-Blind, Phase III KEYNOTE-564 Study

PDF) BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma

ASCO 2023: Pembrolizumab + Axitinib Versus Sunitinib as First-Line Therapy for Advanced Clear Cell RCC: 5-Year Analysis of KEYNOTE-426

PDF) Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Pembrolizumab plus axitinib in first-line continue to demonstrate superiority compared to sunitinib in patients with clear cell renal cell carcinoma - Onco Americas

ASCO 2023: First-Line Lenvatinib + Pembrolizumab Treatment Across Non-Clear Cell Renal Cell Carcinomas: Results of the Phase 2 KEYNOTE-B61 Study

Elizabeth Plimack Fox Chase Cancer Center - Philadelphia PA